Operating
Other Working Capital
Vertex Pharmaceuticals Other Working Capital decreased by 444.8% to -$23.10M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 157.6%, from $40.10M to -$23.10M. Over 3 years (FY 2022 to FY 2025), Other Working Capital shows a downward trend with a 112.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Positive changes suggest a source of cash from optimizing minor balance sheet items, while negative changes indicate cash is being tied up in these categories.
Detailed definition
The aggregate net change in miscellaneous operating assets and liabilities not specifically categorized in major line it...
Peer comparison
This is often used to reconcile net income to cash flow and varies based on a company's specific accounting classifications for 'other' items.
Metric ID:
cf_change_in_other_working_capitalHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$8.85M | -$9.40M | -$4.90M | $11.20M | $26.50M | -$44.60M | -$21.70M | $10.60M | $20.70M | -$18.00M | $36.30M | $21.20M | -$41.30M | $40.10M | -$24.20M | -$72.80M | $6.70M | -$23.10M |
| QoQ Change | — | -6.2% | +47.9% | +328.6% | +136.6% | -268.3% | +51.3% | +148.8% | +95.3% | -187.0% | +301.7% | -41.6% | -294.8% | +197.1% | -160.3% | -200.8% | +109.2% | -444.8% |
| YoY Change | — | — | — | +226.5% | +381.9% | — | -342.9% | -5.4% | -21.9% | +59.6% | +267.3% | +100.0% | -299.5% | +322.8% | -166.7% | -443.4% | +116.2% | -157.6% |
Range-$72.80M – $40.10M
CAGR+25.3%
Avg YoY Growth+2.6%
Median YoY Growth+27.1%
Other Working Capital at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other working capital?
- Vertex Pharmaceuticals (VRTX) reported other working capital of -$23.10M in Q4 2025.
- How has Vertex Pharmaceuticals's other working capital changed year-over-year?
- Vertex Pharmaceuticals's other working capital decreased by 157.6% year-over-year, from $40.10M to -$23.10M.
- What is the long-term trend for Vertex Pharmaceuticals's other working capital?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's other working capital has grown at a 112.6% compound annual growth rate (CAGR), from -$11.80M to -$113.40M.
- What does other working capital mean?
- The cash impact from changes in various smaller business assets and obligations used in daily operations.